Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Reference27 articles.
1. Chen G, Farris MS, Cowling T, Pinto L, Rogoza RM, MacKinnon E, et al. Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: a real-world evidence study. Clin Cardiol. 2021;44(11):1613–20.
2. Sarak B, Savu A, Kaul P, McAlister FA, Welsh RC, Yan AT, et al. Lipid testing, lipid-modifying therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) inhibitor eligibility in 27 979 patients with incident acute coronary syndrome. Circ Cardiovasc Qual Outcomes. 2021;14(4): e006646.
3. Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–50.
4. Sud M, Han L, Koh M, Abdel-Qadir H, Austin Peter C, Farkouh Michael E, et al. Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention. J Am Coll Cardiol. 2020;76(12):1440–50.
5. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082–143.